Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes

Phase 2positivepetrelintidePositive

AI Analysis

Summary

Zealand Pharma announced positive Phase 2 ZUPREME-2 topline results for petrelintide, an amylin analog, in patients with overweight or obesity and type 2 diabetes.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

ZUPREME-2 topline results positive

Importance:7/10

Sentiment:

0.80

Phase 2amylin analogobesitytype 2 diabetespositive data

Related Companies

$ZEAL

Read the original article

Published by GlobeNewswire Pharma on October 7, 2026 5:14 PM

Read Original